微卫星不稳定的癌症中驱动突变的分子演变及其对瘤进展的影响:对UCEC患者的精准医学的影响
Kalpana Sriramadasu1, Senthilkumar Ravichandran2, Yau-Hong Li3
1Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, 804201, Taiwan.
Computers in biology and medicine
|May 1, 2025
概括
癌症驱动突变 (CDM) 与微卫星不稳定性 (MSI) 或不匹配修复缺陷 (MMRd) 的高突变负载不同,影响瘤进化. 瘤突变负担 (TMB) 可以帮助将子宫癌患者分类为向治疗.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 癌症的发展受到遗传变化的影响,包括癌症驱动突变 (CDM) 和微卫星不稳定性 (MSI) 或不匹配修复缺陷 (MMRd) 的高突变负载.
- CDM通常与侵袭性癌症表型和较差的存活率有关,而MSI/MMRd可以促进抗癌免疫力,并改善对免疫检查点抑制剂 (ICI) 疗法的反应.
- 在癌症演变中CDM和MSI/MMRd之间的相互作用尚未完全理解.
研究的目的:
- 研究CDM和MSI/MMRd在子宫体内膜异位癌 (UCEC) 演变中的不同作用.
- 在UCEC中识别关键的遗传驱动因素和免疫调节剂.
- 探索基于分子形状和瘤突变负担 (TMB) 的潜在治疗策略.
主要方法:
- 在UCEC中进行体质突变查,将其与卵巢癌 (OVCA) 和宫平细胞癌 (CSCC) 进行比较.
- 将UCEC患者分类为基于瘤突变负担 (TMB) 截止值7.0个突变/Mb. 的组.
- 对癌症驱动基因 (CDM) 的分析,包括TP53,CTNNB1,PTEN和ARID1A.
- 在GDSC和CTRPv2数据库使用的in silico药物选.
主要成果:
- 与OVCA和CSCC相比,UCEC在癌症驱动基因中的突变率更高.
- 确定TP53突变及其网络是UCEC进展的关键驱动因素.
- 在CTNNB1,PTEN和ARID1A的突变与增强的抗瘤免疫力和更长的生存时间有关.
- 鉴定出GSK-3抑制剂IX和黄素是特定UCEC患者亚组的潜在治疗剂.
结论:
- 免疫调节和耐受性在癌症发展中比CDM发挥更重要的作用,特别是在MSI高/MMRd UCEC中.
- TMB可以作为一种有价值的查工具,用于将UCEC患者与分子和组织病理学数据一起分类.
- 个性化治疗策略可以根据TMB,分子概况和MSI状态来指导,以改善患者的治疗结果.
相关概念视频
Mismatch Repair
4.6K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.6K
Cancers Originate from Somatic Mutations in a Single Cell
11.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.3K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.2K


